EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients M D Anderson Clinical Validation Study



Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients M D Anderson Clinical Validation Study



Breast Cancer Research & Treatment 82(Supplement 1): S11




(PDF 0-2 workdays service: $29.90)

Accession: 035349231

Download citation: RISBibTeXText



Related references

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14. Breast Cancer Research & Treatment 82(Supplement 1): S10-S11, 2003

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence ScoreĀ® assay in oestrogen receptor positive node negative breast cancer. European Journal of Cancer 49(11): 2469-2475, 2014

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. Journal of Clinical Oncology 28(11): 1829-1834, 2010

A Multigene Assay for Predicting the Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Breast Diseases: A Year Book Quarterly 16(3): 219-220, 2005

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. European Journal of Cancer 43(11): 1679-1686, 2007

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 133(3): 1115-1123, 2012

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Annals of Oncology 23(3): 625-631, 2012

Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Research & Treatment 25(2): 127-139, 1993

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. Annals of Oncology 24(9): 2284-2291, 2014

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology 23(16_suppl): 510-510, 2016

Predicting recurrence in axillary node negative breast cancer patients using adaptive artificial intelligence. Breast Cancer Research & Treatment 16(2): 190, 1990

Predicting recurrence in axillary node negative breast cancer patients 10 year follow up results. Proceedings of the American Association for Cancer Research Annual Meeting 33: 212, 1992

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?. European Journal of Cancer 68: 173-175, 2016

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 13(2): 243-250, 2013

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology 28(10): 1677-1683, 2010